I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Atrial septal defect (ASD) is one of the most common congenital heart diseases in adults. Adult patients with unrepaired ASD are at risk of developing major cardiovascular events, especially atrial fibrillation (AF). Transcatheter closure has evolved as a standard therapeutic option for the treatment of ASD in adult patients.\[[@ref1]\] Correction of ASD can not only improve the symptoms and increase exercise tolerance but improve cardiac chamber geometry and hemodynamics.\[[@ref1]\] There is an increased incidence of AF in adult patients with ASD, especially in those over 40 years.\[[@ref2][@ref3]\] AF-related remodeling is believed to underlie the progressive nature of the arrhythmia and contribute to the complexity of long-term management.\[[@ref4][@ref5][@ref6]\] Up to now, little is known about whether transcatheter closure could reverse cardiac remodeling in ASD patients with permanent AF. In this retrospective clinical study, we analyzed ASD patients admitted in our center with and without AF who underwent successful transcatheter closure in an attempt to determine the feasibility of device closure of ASD and observe resultant hemodynamic changes in such patients.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

The clinical medical records of 289 consecutive adult patients older than 40 years who underwent transcatheter ASD closure at our center between October 2009 and October 2013 were analyzed retrospectively. The exclusion criteria were, patients with transthoracic echocardiographic maximal ASD diameter \>40 mm and rims \<5 mm. Of the 289 ASD patients, 63 (21.8%) patients with permanent AF were selected as the case group and the other 226 (78.2%) patients without permanent AF as the control group.

Transcatheter atrial septal defect closure {#sec2-2}
------------------------------------------

The whole procedure was performed under local anesthesia. Complete hemodynamic evaluation right-heart catheterization and pulmonary arteriography were performed. The size of ASD was determined by transthoracic echocardiography during the procedure. The SHSMA^™^ (Shanghai Shape Memory Alloy Co., Ltd., Shanghai, China) ASD occluder was used in all patients. The selected device was 3--6 mm larger than the defect diameter. When the occluder was deployed across the defect, its position and stability were assessed by fluoroscopy and transthoracic echocardiography.

Transthoracic echocardiography {#sec2-3}
------------------------------

Echocardiography was performed using a Sonos iE33 Machine (Philips Medical Systems, USA) according to a standard protocol including color Doppler data. Measurement was performed by two trained cardiologists independently, and any disagreement was solved by discussion. The right and left ventricular volumes were measured in an apical four-chamber view at end-diastole. The right atrial (RA) volume and left atrial (LA) dimension were measured in the same view at end-systole. The left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic dimension (LVEDD) and left ventricular ejection fraction were also measured. Each measurement was averaged from five consecutive cardiac cycles.

Follow-up protocol {#sec2-4}
------------------

All patients were followed-up for at least 6 months after the procedure. An appropriate long-term warfarin dose was used in the case group with the international normalized ratio maintained between 2.0 and 2.5. Aspirin (3--5 mg/kg per day) was administered for 6 months in the control group. Electrocardiographic monitoring, chest X-ray, and transthoracic echocardiography were performed at 1 and 6 months after the procedure. The cardiac geometric location of the occluder, thrombi, valvular regurgitation and residual shunt were also evaluated by transthoracic echocardiography.

Statistical analysis {#sec2-5}
--------------------

Nominal data presented as frequencies and percentages. Continuous data are presented as median and range if not normally distributed and as mean ± standard deviation if normally distributed. Nominal data between groups were compared using Chi-square or Fisher\'s exact test. The variables of pre and postprocedure were compared using paired, two-sided Student\'s *t*-test. Continuous data between groups were compared using unpaired, two-sided Student\'s *t*-test. *P* \< 0.05 was defined as significant. Data were analyzed using Statistical Package for Social Sciences, version 20.0, for Mac (SPSS Inc., Chicago, Illinois, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Clinical characteristics {#sec2-6}
------------------------

In the case group, there were 27 (42.9%) males and 36 (57.1%) females with a mean age of 68.3 ± 15.4 years. In the control group, there were 99 (43.8%) males and 127 (56.2%) females with a mean age of 47.4 ± 13.9 years. Patients in the case group were significantly older than those in the control group (*P* \< 0.001). The clinical characteristics of the two groups are listed in [Table 1](#T1){ref-type="table"}.

###### 

Baseline clinical characteristics

  Variable                     Case group (*n* = 63)   Control group (*n* = 226)   *P*
  ---------------------------- ----------------------- --------------------------- ---------
  Age (years)                  68.3 ± 15.4             47.4 ± 13.9                 \<0.001
  Female, *n* (%)              36 (57.1)               127 (56.2)                  0.947
  ASD diameter (mm)            17.8 ± 9.3              18.4 ± 8.9                  0.738
  Device size (mm)             22.6 ± 7.2              23.1 ± 6.6                  0.681
  Hypertension, *n* (%)        24 (38.1)               67 (29.6)                   0.216
  Diabetes mellitus, *n* (%)   5 (7.9)                 9 (4.0)                     0.201
  Cardiac function, *n* (%)                                                        
   NYHA I                      25 (39.7)               95 (42.0)                   0.756
   NYHA II                     19 (30.2)               129 (57.1)                  \<0.001
   NYHA III                    9 (14.3)                2 (0.9)                     \<0.001

ASD: Atrial septal defect; NYHA: New York Heart Association.

Cardiac geometry before and after closure in patients with atrial fibrillation {#sec2-7}
------------------------------------------------------------------------------

The cardiac geometry was significantly improved immediately after the procedure and during the follow-up period in both groups. In the case group, the right ventricular (RV) end-diastolic volume decreased from 81.57 ± 31.47 ml preprocedure to 62.92 ± 19.07 ml postprocedure during a median interval of 6 months after closure (*P* \< 0.001), and the RA volume decreased from 106.93 ± 54.17 ml preprocedure to 79.07 ± 40.39 ml postprocedure (*P* \< 0.001). The LA dimension, LVESD, LVEDD and left ventricular ejection fraction remained unchanged significantly \[[Table 2](#T2){ref-type="table"}\].

###### 

Echocardiographic variables before and 6 months after ASD closure

  Variable             Case group (*n* = 63)   Control group (*n* = 226)                                             
  -------------------- ----------------------- --------------------------- --------- --------------- --------------- ---------
  LVESD (mm)           26.35 ± 2.92            26.91 ± 2.95                0.186     23.63 ± 3.26    23.89 ± 2.95    0.698
  LVEDD (mm)           40.71 ± 4.24            41.55 ± 3.51                0.132     37.28 ± 4.44    36.17 ± 3.91    0.063
  LVEF (%)             65.18 ± 4.66            64.83 ± 4.38                0.727     66.21 ± 3.12    65.89 ± 3.92    0.725
  LA dimensions (mm)   42.70 ± 9.55            40.96 ± 10.07               0.263     35.19 ± 7.43    33.97 ± 8.15    0.365
  RV volume (ml)       81.57 ± 31.47           62.92 ± 19.07               \<0.001   76.72 ± 27.56   59.39 ± 10.21   \<0.001
  RA volume (ml)       106.93 ± 54.17          79.07 ± 40.39               \<0.001   84.27 ± 32.68   43.21 ± 20.48   \<0.001

LVESD: Left ventricular end-systolic dimensions; LVEDD: Left ventricular end-diastolic dimensions; LVEF: Left ventricular ejection fraction; LA: Left atrial; RV: Right ventricular; RA: Right atrial; ASD: Atrial septal defect.

Cardiac geometry before and after closure in patients without atrial fibrillation {#sec2-8}
---------------------------------------------------------------------------------

Both RV end-diastolic volume and RA volume decreased significantly in the control group during the follow-up period from 76.72 ± 27.56 to 59.39 ± 10.21 ml (*P* \< 0.001) and from 84.27 ± 32.68 to 43.21 ± 20.48 ml, respectively (*P* \< 0.001). The LA dimension, LVESD, LVEDD and left ventricular ejection fraction remained unchanged significantly \[[Table 2](#T2){ref-type="table"}\].

Comparison of cardiac geometric change between the two groups {#sec2-9}
-------------------------------------------------------------

The RV and RA volumes were decreased significantly in both the groups during the 6 months follow-up period after closure. Changes of the RV volume and RA volume in the case group were significantly smaller as compared with those of the control group (20.74 ± 10.68 ml to 24.69 ± 9.46 ml, *P* = 0.005; 27.53 ± 12.68 ml to 36.63 ± 13.79 ml, *P* \< 0.001) \[[Figure 1](#F1){ref-type="fig"}\]. Of the 63 patients with permanent AF in the case group, 25 (39.7%), 29 (46.0%), and 9 (14.3%) patients were considered to have New York Heart Association (NYHA) Class I, II and III, respectively. Of the 226 patients in the control group, 95 (42.0%), 129 (57.1%), and 2 (0.9%) were graded as having NYHA Class I, II and III, respectively. NYHA functional classification was improved in both the groups after the procedure \[[Figure 2](#F2){ref-type="fig"}\].

![Changes of the right ventricular (RV) volume and right atrial (RA) volume. The 6 months follow-up period showed that changes of the RV volume and RA volume in the case group were significantly less than those in the control group (\**P* \< 0.05; RV: Right ventricular; RA: Right atrial).](CMJ-128-780-g001){#F1}

![Heart function improvement in both the groups. In the case group, 25 (39.7%), 29 (46.0%) and 9 (14.3%) patients were considered to have NYHA Class I, II and III. In the control group, 95 (42.0%), 129 (57.1%) and 2 (0.9%) were graded as having NYHA Class I, II and III. NYHA cardiac function was improved in both the groups after the procedure (NYHA: New York Heart Association).](CMJ-128-780-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Our study demonstrated that the transcatheter closure of ASD in patients with permanent AF is safe and feasible as in the case with patients without AF. Transcatheter ASD closure can improve the patient\'s quality of life and cardiac remodeling even in patients with permanent AF.\[[@ref7][@ref8]\] In addition, it can improve the symptoms and reverse remodeling of the right-heart in adults of all ages.\[[@ref1]\] Majunke *et al*.\[[@ref9]\] studied 650 adult ASD patients and concluded that ASD in adults is safe and effective, offering excellent long-term outcomes. Patel *et al*.\[[@ref8]\] also showed that ASD closure could decrease the RV size and improve the clinical symptoms significantly with an extremely high success rate. In our study, the NYHA cardiac function was improved in both groups after transcatheter closure. The right-heart size was decreased significantly in all patients. Although most adult ASD patients with permanent AF in our series were older and often had significant comorbidities, our study still brought encouraging outcomes in the cardiac function and structural improvement. Above all, transcatheter ASD closure should be recommended as the treatment of choice in patients with and without permanent AF.\[[@ref10]\]

The present study showed that the magnitude of the decrease in the RA and RV size in patients with permanent AF was smaller than that in patients without AF. This may be partly due to the older age of the patients in the case group. Patients with significant shunting are more likely to develop RV failure and atrial tachycardia, which can lead to significant morbidity and potential mortality.\[[@ref1]\] AF is more frequently seen in older patients, and not a few patients may continue to experience fibrillation after ASD closure.\[[@ref11][@ref12]\] Rosas *et al*.\[[@ref13]\] analyzed 200 un-operated patients over 40 years and found that age was a predictor of poor outcomes.\[[@ref13]\] Thus, ASD closure should be considered as early as possible after confirmation of the diagnosis.

However, many adult ASD patients in China remain unrepaired even though the transcatheter procedure has been well practiced for nearly two decades.\[[@ref14][@ref15]\] One reason is the unbalanced development of the medical conditions; for instance echocardiography remains unavailable and unaccessible in many central and western regions of China, especially in remote mountainous areas, and therefore ASD cannot be detected at an early age in many patients. Another reason is the economic gap between the urban and rural populations. Although ASD was detected in some patients during their youth hood, treatment was often delayed because of the economic reason. These patients often progressed to right-heart failure and AF. Taniguchi *et al*.\[[@ref2]\] analyzed nine old ASD patients with permanent AF and found that the NYHA cardiac function was improved in all patients. RV remodeling was also improved significantly in terms of both right and left diameter ratios and plasma B-type natriuretic peptide level. Our study confirmed that both the structure and function of the right-heart were improved significantly in all ASD patients with AF after occlusion. As a result, the quality of life in these patients was also improved significantly. It can be concluded that the closure of the defect is still the right thing to do in patients with ASD and AF.\[[@ref16]\]

Additionally, as patients with AF are at high risk of developing ischemic events, anticoagulation therapy should be considered instead of antiplatelet medication.\[[@ref17][@ref18]\] No device thrombosis or major bleeding complications were observed during the 6 months follow-up period in both the groups, indicating that anticoagulation therapy with warfarin is safety and effective. In addition, given potential thrombi in the LA appendage, transesophageal echocardiography should be performed before the procedure. In the present study, transesophageal echocardiography was not taken in all patients with AF. However, no ischemic complication occurred during the follow-up period, partly because of the relatively small sample size in the case group.

The present study has several limitations, including those inherent to the retrospective design and the relatively short follow-up period. Although thrombus formation was not detected during the follow-up period, long-term follow-up evaluation is mandatory. Evaluation by transesophageal echocardiography may be helpful to examine thrombus formation more closely.

In conclusion, closure of ASD in patients with permanent AF is safe and feasible. Our study has demonstrated that the procedure can improve cardiac remodeling and heart function in patients both with and without AF, even in patients with permanent AF.
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